Portfolio Holdings Detail for ISIN IE00BDZVHG35
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 67
Stock Name / Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer Blackrock

ETF Ticker BTEE(USD) LSE
ETF Ticker BTEE.L(GBP) LSE

Holdings detail for KYMR

Stock Name	Kymera Therapeutics Inc
Ticker	KYMR(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US5015751044

Show aggregate KYMR holdings

News associated with KYMR

Kymera Therapeutics (NASDAQ:KYMR) Now Covered by Barclays: Barclays initiated coverage on shares of Kymera Therapeutics (NASDAQ:KYMR – Free Report) in a report published on Wednesday, Marketbeat reports. The firm issued an overweight rating and a $60.00 price target on the stock. Other research analysts have also issued research reports about the stock. BTIG Research reiterated a “buy” rating and set a $59.00 […] - 2025-09-18 05:13:29
Analysts Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) PT at $58.76: Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) has received an average rating of “Buy” from the nineteen analysts that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, fifteen have given a buy recommendation and three have assigned a strong buy recommendation to the company. The […] - 2025-09-08 02:50:52
Wednesday's ETF with Unusual Volume: FYC: The First Trust Small Cap Growth AlphaDEX Fund ETF is seeing unusually high volume in afternoon trading Wednesday, with over 111,000 shares traded versus three month average volume of about 27,000. Shares of FYC were up about 0.4% on the day. Components of that ETF with the hi - 2025-08-27 13:50:50
Kymera Therapeutics (NASDAQ:KYMR) Rating Lowered to Sell at Wall Street Zen: Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday. Other analysts have also recently issued reports about the stock. Oppenheimer restated an “outperform” rating and set a $53.00 target price (down from $56.00) on […] - 2025-08-18 04:46:57
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $59.11 Consensus PT from Analysts: Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) has earned an average recommendation of “Buy” from the twenty brokerages that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold rating, sixteen have given a buy rating and three have assigned a strong buy rating to the company. […] - 2025-08-14 02:32:51
Kymera Therapeutics (NASDAQ:KYMR) Shares Gap Down Following Weak Earnings: Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report)’s stock price gapped down prior to trading on Monday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $40.62, but opened at $38.16. Kymera Therapeutics shares last traded at $39.34, with a volume of 134,694 shares trading hands. The company reported […] - 2025-08-13 02:17:07
Notable Two Hundred Day Moving Average Cross - KYMR: In trading on Monday, shares of Kymera Therapeutics Inc (Symbol: KYMR) crossed below their 200 day moving average of $39.13, changing hands as low as $36.65 per share. Kymera Therapeutics Inc shares are currently trading off about 2.8% on the day. The chart below shows the one - 2025-08-11 12:49:18
Kymera Revenue Drops 55 Percent in Q2: Key PointsGAAP revenue declined sharply from $25.7 million in Q2 2024 to $11.5 million in Q2 2025, missing analyst expectations by 48.4% for Q2 2025 (GAAP). - 2025-08-11 08:28:41
Kymera Therapeutics (NASDAQ:KYMR) Now Covered by Analysts at Morgan Stanley: Morgan Stanley assumed coverage on shares of Kymera Therapeutics (NASDAQ:KYMR – Free Report) in a research report released on Thursday morning. The brokerage issued an overweight rating and a $70.00 price objective on the stock. A number of other research analysts also recently issued reports on the company. Guggenheim reissued a “buy” rating and issued […] - 2025-07-04 04:59:46
Bvf Partners L. P/Il Buys 317,167 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) Stock: Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) Director Bvf Partners L. P/Il purchased 317,167 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, June 30th. The shares were bought at an average cost of $44.00 per share, for a total transaction of $13,955,348.00. Following the completion of the transaction, the director […] - 2025-07-03 05:26:56
Wells Fargo & Company Lowers Kymera Therapeutics (NASDAQ:KYMR) Price Target to $53.00: Kymera Therapeutics (NASDAQ:KYMR – Free Report) had its target price trimmed by Wells Fargo & Company from $57.00 to $53.00 in a report released on Thursday morning,Benzinga reports. They currently have an overweight rating on the stock. Other equities analysts have also issued research reports about the company. Wall Street Zen upgraded Kymera Therapeutics from […] - 2025-06-27 04:46:43
We Did The Math TMSL Can Go To $38: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-06-10 08:53:34
Kymera Therapeutics (NASDAQ:KYMR) Upgraded by Bank of America to “Buy” Rating: Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) was upgraded by research analysts at Bank of America from a “neutral” rating to a “buy” rating in a research note issued to investors on Monday, Marketbeat.com reports. The firm currently has a $51.00 price target on the stock. Bank of America‘s price objective points to a potential […] - 2025-06-04 02:50:56
Kymera Therapeutics (NASDAQ:KYMR) Sees Large Volume Increase on Analyst Upgrade: Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) shares saw strong trading volume on Tuesday after JPMorgan Chase & Co. raised their price target on the stock from $57.00 to $64.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. 961,245 shares changed hands during mid-day trading, an increase of 62% from […] - 2025-06-04 02:01:25
Universal Beteiligungs und Servicegesellschaft mbH Invests $4.61 Million in Kymera Therapeutics, Inc. (NASDAQ:KYMR): Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 114,587 shares of the company’s stock, valued at approximately $4,610,000. Universal Beteiligungs und […] - 2025-06-02 05:36:54
Bank of America Corp DE Trims Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR): Bank of America Corp DE cut its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 43.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 62,260 shares of the company’s stock after selling 48,772 shares during the quarter. Bank of America […] - 2025-06-02 04:38:48
BNP Paribas Financial Markets Makes New $396,000 Investment in Kymera Therapeutics, Inc. (NASDAQ:KYMR): BNP Paribas Financial Markets acquired a new stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 9,838 shares of the company’s stock, valued at approximately $396,000. Several other hedge […] - 2025-05-26 04:24:47
D. E. Shaw & Co. Inc. Lowers Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR): D. E. Shaw & Co. Inc. cut its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 56.1% during the fourth quarter, Holdings Channel reports. The institutional investor owned 82,578 shares of the company’s stock after selling 105,619 shares during the quarter. D. E. Shaw & Co. Inc.’s holdings in Kymera Therapeutics were worth […] - 2025-05-19 05:12:56
Northern Trust Corp Grows Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR): Northern Trust Corp raised its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 14.0% during the 4th quarter, Holdings Channel.com reports. The firm owned 437,833 shares of the company’s stock after acquiring an additional 53,658 shares during the quarter. Northern Trust Corp’s holdings in Kymera Therapeutics were worth $17,614,000 as of […] - 2025-05-15 05:38:47
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Sold by Comerica Bank: Comerica Bank cut its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 45.8% in the fourth quarter, Holdings Channel.com reports. The firm owned 20,631 shares of the company’s stock after selling 17,442 shares during the quarter. Comerica Bank’s holdings in Kymera Therapeutics were worth $830,000 at the end of the most recent reporting […] - 2025-05-14 05:19:05
Guggenheim Reaffirms “Buy” Rating for Kymera Therapeutics (NASDAQ:KYMR): Kymera Therapeutics (NASDAQ:KYMR – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at Guggenheim in a research report issued on Monday,Benzinga reports. They presently have a $52.00 price target on the stock. Guggenheim’s price objective points to a potential upside of 66.99% from the company’s current price. A number of […] - 2025-05-14 03:10:53
Tower Research Capital LLC TRC Increases Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR): Tower Research Capital LLC TRC increased its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 95.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 4,812 shares of the company’s stock after purchasing an additional 2,350 shares during the […] - 2025-05-06 05:16:52
Marshall Wace LLP Sells 110,846 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR): Marshall Wace LLP decreased its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 94.2% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 6,835 shares of the company’s stock after selling 110,846 shares during the period. Marshall Wace LLP’s holdings in […] - 2025-05-05 05:04:51
Wells Fargo & Company MN Has $883,000 Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR): Wells Fargo & Company MN grew its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 51.8% during the fourth quarter, Holdings Channel reports. The firm owned 21,939 shares of the company’s stock after acquiring an additional 7,487 shares during the quarter. Wells Fargo & Company MN’s holdings in Kymera Therapeutics were worth $883,000 […] - 2025-05-01 04:35:02
Franklin Resources Inc. Acquires 8,927 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR): Franklin Resources Inc. raised its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 30.3% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 38,367 shares of the company’s stock after acquiring an additional 8,927 shares during the period. Franklin Resources Inc. owned approximately 0.06% […] - 2025-04-15 05:32:48
Alliancebernstein L.P. Cuts Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR): Alliancebernstein L.P. lessened its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 29.2% during the fourth quarter, Holdings Channel.com reports. The firm owned 88,246 shares of the company’s stock after selling 36,368 shares during the quarter. Alliancebernstein L.P.’s holdings in Kymera Therapeutics were worth $3,550,000 as of its most recent filing with the […] - 2025-04-15 04:50:48
Norges Bank Invests $3.67 Million in Kymera Therapeutics, Inc. (NASDAQ:KYMR): Norges Bank acquired a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 91,231 shares of the company’s stock, valued at approximately $3,670,000. Several other large investors have also bought and […] - 2025-04-11 05:12:59
Brokerages Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) PT at $56.36: Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) has earned an average rating of “Moderate Buy” from the fifteen research firms that are presently covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a hold recommendation, eleven have given a buy recommendation and one has assigned a strong buy recommendation to […] - 2025-04-11 03:08:47
Vanguard Group Inc. Acquires 133,546 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR): Vanguard Group Inc. grew its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 2.8% during the fourth quarter, Holdings Channel reports. The institutional investor owned 4,887,312 shares of the company’s stock after purchasing an additional 133,546 shares during the quarter. Vanguard Group Inc. owned about 0.08% of Kymera Therapeutics worth $196,617,000 […] - 2025-04-07 04:34:48
Teacher Retirement System of Texas Increases Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR): Teacher Retirement System of Texas raised its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 35.8% in the fourth quarter, Holdings Channel reports. The institutional investor owned 11,490 shares of the company’s stock after purchasing an additional 3,026 shares during the period. Teacher Retirement System of Texas’ holdings in Kymera Therapeutics were worth […] - 2025-04-01 04:40:45

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) KYMR holdings

Date	Number of KYMR Shares Held	Base Market Value of KYMR Shares	Local Market Value of KYMR Shares	Change in KYMR Shares Held	Change in KYMR Base Value	Current Price per KYMR Share Held	Previous Price per KYMR Share Held
2025-12-03 (Wednesday)	50,294	USD 3,318,901	USD 3,318,901	0	USD 86,506	USD 65.99	USD 64.27
2025-12-02 (Tuesday)	50,294	USD 3,232,395	USD 3,232,395	1,785	USD -10,917	USD 64.27	USD 66.86
2025-12-01 (Monday)	48,509	USD 3,243,312	USD 3,243,312	0	USD -49,479	USD 66.86	USD 67.88
2025-11-28 (Friday)	48,509	USD 3,292,791	USD 3,292,791	119	USD 9,046	USD 67.88	USD 67.86
2025-11-27 (Thursday)	48,390	USD 3,283,745	USD 3,283,745	0	USD 0	USD 67.86	USD 67.86
2025-11-26 (Wednesday)	48,390	USD 3,283,745	USD 3,283,745	357	USD 111,646	USD 67.86	USD 66.04
2025-11-25 (Tuesday)	48,033	USD 3,172,099	USD 3,172,099	595	USD 60,641	USD 66.04	USD 65.59
2025-11-24 (Monday)	47,438	USD 3,111,458	USD 3,111,458	119	USD -13,489	USD 65.59	USD 66.04
2025-11-21 (Friday)	47,319	USD 3,124,947	USD 3,124,947	0	USD 66,720	USD 66.04	USD 64.63
2025-11-20 (Thursday)	47,319	USD 3,058,227	USD 3,058,227	-476	USD -39,845	USD 64.63	USD 64.82
2025-11-19 (Wednesday)	47,795	USD 3,098,072	USD 3,098,072	119	USD 32,028	USD 64.82	USD 64.31
2025-11-18 (Tuesday)	47,676	USD 3,066,044	USD 3,066,044	714	USD 55,780	USD 64.31	USD 64.1
2025-11-17 (Monday)	46,962	USD 3,010,264	USD 3,010,264	238	USD -23,993	USD 64.1	USD 64.94

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of KYMR by Blackrock for IE00BDZVHG35

Show aggregate share trades of KYMR

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-12-02 BUY 1,785 67.075 63.690 64.028 USD 114,291 43.02
2025-11-28 BUY 119 68.195 67.090 67.200 USD 7,997 42.77
2025-11-26 BUY 357 68.435 66.120 66.352 USD 23,687 42.52
2025-11-26 BUY 357 68.435 66.120 66.352 USD 23,687 42.52
2025-11-25 BUY 595 67.195 63.860 64.194 USD 38,195 42.40
2025-11-24 BUY 119 68.800 64.300 64.750 USD 7,705 42.28
2025-11-20 SELL -476 68.300 64.055 64.480 USD -30,692 42.04 Loss of -10,679 on sale
2025-11-19 BUY 119 66.445 64.195 64.420 USD 7,666 41.93
2025-11-18 BUY 714 65.580 62.910 63.177 USD 45,108 41.81
2025-11-17 BUY 238 65.650 63.390 63.616 USD 15,141 41.69
2025-11-14 BUY 119 68.455 62.130 62.763 USD 7,469 41.57
2025-11-12 BUY 119 65.690 62.960 63.233 USD 7,525 41.34
2025-11-10 BUY 119 62.100 58.865 59.189 USD 7,043 41.11
2025-11-06 BUY 119 61.245 59.200 59.405 USD 7,069 40.91
2025-11-04 BUY 119 61.580 55.660 56.252 USD 6,694 40.70
2025-10-30 BUY 595 61.786 59.240 59.495 USD 35,399 40.36
2025-10-29 BUY 238 60.030 61.810 61.632 USD 14,668 40.25
2025-10-22 SELL -476 55.800 59.190 58.851 USD -28,013 39.71 Loss of -9,113 on sale
2025-10-20 BUY 238 60.500 61.825 61.693 USD 14,683 39.48
2025-10-17 BUY 595 59.830 61.610 61.432 USD 36,552 39.36
2025-10-15 BUY 952 62.890 63.290 63.250 USD 60,214 39.22
2025-10-03 BUY 826 57.900 59.000 58.890 USD 48,643 38.99
2025-10-02 BUY 118 56.000 56.145 56.131 USD 6,623 38.89
2025-09-30 BUY 236 56.600 58.930 58.697 USD 13,852 38.68
2025-09-26 BUY 236 56.250 56.810 56.754 USD 13,394 38.45
2025-09-25 BUY 236 53.735 53.840 53.830 USD 12,704 38.36
2025-09-18 BUY 113 51.160 51.800 51.736 USD 5,846 38.28
2025-09-17 BUY 339 48.120 50.690 50.433 USD 17,097 38.22
2025-07-17 SELL -226 46.350 46.925 46.867 USD -10,592 38.00 Loss of -2,004 on sale
2025-07-16 BUY 618 45.510 46.000 45.951 USD 28,398 37.95
2025-07-11 SELL -888 44.480 45.150 45.083 USD -40,034 37.82 Loss of -6,453 on sale
2025-07-02 BUY 6,105 44.530 45.460 45.367 USD 276,966 37.62
2025-06-25 BUY 222 46.470 46.820 46.785 USD 10,386 37.42
2025-06-20 BUY 710 45.870 46.660 46.581 USD 33,073 37.22
2025-06-11 BUY 218 48.390 50.270 50.082 USD 10,918 36.71
2025-06-10 BUY 218 48.600 49.020 48.978 USD 10,677 36.62
2025-06-04 SELL -109 44.260 45.450 45.331 USD -4,941 36.31 Loss of -984 on sale
2025-04-23 BUY 109 30.700 31.070 31.033 USD 3,383 37.64
2025-04-10 SELL -872 22.400 23.430 23.327 USD -20,341 38.86 Profit of 13,541 on sale
2025-04-08 SELL -109 21.050 23.778 23.505 USD -2,562 39.23 Profit of 1,714 on sale
2025-04-07 SELL -109 22.010 22.480 22.433 USD -2,445 39.43 Profit of 1,853 on sale
2025-04-04 SELL -550 22.070 22.990 22.898 USD -12,594 39.64 Profit of 9,206 on sale
2025-04-01 BUY 1,279 25.235 27.365 27.152 USD 34,727 39.97
2025-03-31 SELL -321 27.370 28.750 28.612 USD -9,184 40.12 Profit of 3,695 on sale
2025-03-21 BUY 1,478 32.540 33.900 33.764 USD 49,903 40.81
2025-03-14 SELL -1,632 34.370 34.990 34.928 USD -57,002 41.29 Profit of 10,389 on sale
2025-03-07 SELL -204 32.890 33.560 33.493 USD -6,833 41.88 Profit of 1,711 on sale
2025-03-04 SELL -102 30.680 30.960 30.932 USD -3,155 42.37 Profit of 1,166 on sale
2025-02-25 BUY 204 34.710 35.725 35.623 USD 7,267 43.23
2025-02-19 SELL -102 37.650 38.240 38.181 USD -3,894 43.71 Profit of 564 on sale
2025-02-13 BUY 306 36.630 36.750 36.738 USD 11,242 44.25
2025-02-12 BUY 102 35.150 35.510 35.474 USD 3,618 44.44
2025-02-11 BUY 408 34.410 36.150 35.976 USD 14,678 44.65
2024-12-30 SELL -3,491 39.320 39.840 39.788 USD -138,900 46.81 Profit of 24,523 on sale
2024-11-18 SELL -1,665 42.410 43.080 43.013 USD -71,617 48.33 Profit of 8,859 on sale
2024-11-08 SELL -111 50.950 51.130 51.112 USD -5,673 48.03 Loss of -342 on sale
2024-10-21 SELL -111 46.560 46.885 46.852 USD -5,201 0.00 Loss of -5,201 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-12-02	BUY	1,785	67.075	63.690	64.028	USD 114,291	43.02
2025-11-28	BUY	119	68.195	67.090	67.200	USD 7,997	42.77
2025-11-26	BUY	357	68.435	66.120	66.352	USD 23,687	42.52
2025-11-26	BUY	357	68.435	66.120	66.352	USD 23,687	42.52
2025-11-25	BUY	595	67.195	63.860	64.194	USD 38,195	42.40
2025-11-24	BUY	119	68.800	64.300	64.750	USD 7,705	42.28
2025-11-20	SELL	-476	68.300	64.055	64.480	USD -30,692	42.04 Loss of -10,679 on sale
2025-11-19	BUY	119	66.445	64.195	64.420	USD 7,666	41.93
2025-11-18	BUY	714	65.580	62.910	63.177	USD 45,108	41.81
2025-11-17	BUY	238	65.650	63.390	63.616	USD 15,141	41.69
2025-11-14	BUY	119	68.455	62.130	62.763	USD 7,469	41.57
2025-11-12	BUY	119	65.690	62.960	63.233	USD 7,525	41.34
2025-11-10	BUY	119	62.100	58.865	59.189	USD 7,043	41.11
2025-11-06	BUY	119	61.245	59.200	59.405	USD 7,069	40.91
2025-11-04	BUY	119	61.580	55.660	56.252	USD 6,694	40.70
2025-10-30	BUY	595	61.786	59.240	59.495	USD 35,399	40.36
2025-10-29	BUY	238	60.030	61.810	61.632	USD 14,668	40.25
2025-10-22	SELL	-476	55.800	59.190	58.851	USD -28,013	39.71 Loss of -9,113 on sale
2025-10-20	BUY	238	60.500	61.825	61.693	USD 14,683	39.48
2025-10-17	BUY	595	59.830	61.610	61.432	USD 36,552	39.36
2025-10-15	BUY	952	62.890	63.290	63.250	USD 60,214	39.22
2025-10-03	BUY	826	57.900	59.000	58.890	USD 48,643	38.99
2025-10-02	BUY	118	56.000	56.145	56.131	USD 6,623	38.89
2025-09-30	BUY	236	56.600	58.930	58.697	USD 13,852	38.68
2025-09-26	BUY	236	56.250	56.810	56.754	USD 13,394	38.45
2025-09-25	BUY	236	53.735	53.840	53.830	USD 12,704	38.36
2025-09-18	BUY	113	51.160	51.800	51.736	USD 5,846	38.28
2025-09-17	BUY	339	48.120	50.690	50.433	USD 17,097	38.22
2025-07-17	SELL	-226	46.350	46.925	46.867	USD -10,592	38.00 Loss of -2,004 on sale
2025-07-16	BUY	618	45.510	46.000	45.951	USD 28,398	37.95
2025-07-11	SELL	-888	44.480	45.150	45.083	USD -40,034	37.82 Loss of -6,453 on sale
2025-07-02	BUY	6,105	44.530	45.460	45.367	USD 276,966	37.62
2025-06-25	BUY	222	46.470	46.820	46.785	USD 10,386	37.42
2025-06-20	BUY	710	45.870	46.660	46.581	USD 33,073	37.22
2025-06-11	BUY	218	48.390	50.270	50.082	USD 10,918	36.71
2025-06-10	BUY	218	48.600	49.020	48.978	USD 10,677	36.62
2025-06-04	SELL	-109	44.260	45.450	45.331	USD -4,941	36.31 Loss of -984 on sale
2025-04-23	BUY	109	30.700	31.070	31.033	USD 3,383	37.64
2025-04-10	SELL	-872	22.400	23.430	23.327	USD -20,341	38.86 Profit of 13,541 on sale
2025-04-08	SELL	-109	21.050	23.778	23.505	USD -2,562	39.23 Profit of 1,714 on sale
2025-04-07	SELL	-109	22.010	22.480	22.433	USD -2,445	39.43 Profit of 1,853 on sale
2025-04-04	SELL	-550	22.070	22.990	22.898	USD -12,594	39.64 Profit of 9,206 on sale
2025-04-01	BUY	1,279	25.235	27.365	27.152	USD 34,727	39.97
2025-03-31	SELL	-321	27.370	28.750	28.612	USD -9,184	40.12 Profit of 3,695 on sale
2025-03-21	BUY	1,478	32.540	33.900	33.764	USD 49,903	40.81
2025-03-14	SELL	-1,632	34.370	34.990	34.928	USD -57,002	41.29 Profit of 10,389 on sale
2025-03-07	SELL	-204	32.890	33.560	33.493	USD -6,833	41.88 Profit of 1,711 on sale
2025-03-04	SELL	-102	30.680	30.960	30.932	USD -3,155	42.37 Profit of 1,166 on sale
2025-02-25	BUY	204	34.710	35.725	35.623	USD 7,267	43.23
2025-02-19	SELL	-102	37.650	38.240	38.181	USD -3,894	43.71 Profit of 564 on sale
2025-02-13	BUY	306	36.630	36.750	36.738	USD 11,242	44.25
2025-02-12	BUY	102	35.150	35.510	35.474	USD 3,618	44.44
2025-02-11	BUY	408	34.410	36.150	35.976	USD 14,678	44.65
2024-12-30	SELL	-3,491	39.320	39.840	39.788	USD -138,900	46.81 Profit of 24,523 on sale
2024-11-18	SELL	-1,665	42.410	43.080	43.013	USD -71,617	48.33 Profit of 8,859 on sale
2024-11-08	SELL	-111	50.950	51.130	51.112	USD -5,673	48.03 Loss of -342 on sale
2024-10-21	SELL	-111	46.560	46.885	46.852	USD -5,201	0.00 Loss of -5,201 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of KYMR

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	309,046	3,591	440,760	70.1%
2025-09-18	223,301	7,626	444,002	50.3%
2025-09-17	307,071	1,955	434,446	70.7%
2025-09-16	234,451	3,639	317,172	73.9%
2025-09-15	202,005	2,548	260,745	77.5%
2025-09-12	139,517	307	207,721	67.2%
2025-09-11	124,303	300	190,842	65.1%
2025-09-10	142,312	0	254,156	56.0%
2025-09-09	112,495	0	199,835	56.3%
2025-09-08	125,694	0	243,191	51.7%
2025-09-05	136,137	4,123	196,490	69.3%
2025-09-04	212,656	0	413,751	51.4%
2025-09-03	150,086	0	325,025	46.2%
2025-09-02	173,311	0	513,103	33.8%
2025-08-29	72,127	27	174,510	41.3%
2025-08-28	69,778	5	227,826	30.6%
2025-08-27	147,866	0	265,304	55.7%
2025-08-26	119,682	471	140,473	85.2%
2025-08-25	76,967	0	113,682	67.7%
2025-08-22	135,604	2,740	192,354	70.5%
2025-08-21	125,730	0	181,377	69.3%
2025-08-20	119,391	0	150,089	79.5%
2025-08-19	129,153	0	198,058	65.2%
2025-08-18	176,394	200	254,714	69.3%
2025-08-15	269,401	700	341,184	79.0%
2025-08-14	273,156	1,009	390,021	70.0%
2025-08-13	208,680	0	267,116	78.1%
2025-08-12	236,621	94	360,461	65.6%
2025-08-11	430,146	0	664,953	64.7%
2025-08-08	189,815	0	384,750	49.3%
2025-08-07	128,981	0	203,181	63.5%
2025-08-06	90,389	3	157,957	57.2%
2025-08-05	36,394	0	64,189	56.7%
2025-08-04	76,200	0	104,248	73.1%
2025-08-01	89,233	0	115,453	77.3%
2025-07-31	105,933	800	152,574	69.4%
2025-07-30	129,479	0	204,164	63.4%
2025-07-29	155,236	0	232,322	66.8%
2025-07-28	161,674	0	233,442	69.3%
2025-07-25	78,056	80	164,296	47.5%
2025-07-24	71,971	0	91,137	79.0%
2025-07-23	60,582	0	90,359	67.0%
2025-07-22	72,103	0	157,347	45.8%
2025-07-21	144,850	1,363	258,325	56.1%
2025-07-18	170,167	80	221,778	76.7%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer	Blackrock
ETF Ticker	BTEE(USD) LSE
ETF Ticker	BTEE.L(GBP) LSE